You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202331 - 202340 of 204843 results
  1. Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes

    SBC: POP Biotechnologies Inc.            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to 14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified. Harnessing the immune system to prevent or remove Aβ and/or tau pathologies represents a promising disease- modifying therapeutic approach for the tr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Restoration of Muscular Function Following Direct Muscle Neurotization

    SBC: Renerva, LLC            Topic: 107

    Summary/Abstract More than 500,000 surgical procedures are performed annually in the US to address peripheral nerve injury (PNI), at a cost of more than $1.1B. PNI and their sequelae affect more than 20 million Americans, with total economic impacts in excess of $150B annually. Despite advances in microsurgical techniques and the inherent ability of the peripheral nervous system to regenerate, few ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. An R2 non-neuroinvasive herpes simplex virus type 2 vaccine

    SBC: THYREOS INC            Topic: NIAID

    PROJECT SUMMARY There is an unmet need for a herpes simplex virus (HSV) vaccine. We propose to develop a live-attenuated HSV-2 vaccine based on our R2 technology platform. R2 vaccines show unprecedented safety and efficacy in animal models, and offer antigenicity superior to subunit/mRNA and single-round vaccine designs. R2 vaccines are also the first live-attenuated alphaherpesvirus vaccines that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Translational development of novel CRISPR approach to treat genomic duplications

    SBC: MYOFINITY BIOSCIENCES INC            Topic: NIAMS

    PROJECT ABSTRACT The goal of this Phase I STTR project is to accomplish key milestones in commercializing a novel SaCas9 nickase-based system (CRD-002) to treat dystrophinopathies in order to restore the production of healthy, endogenous full-length dystrophin protein otherwise compromised by duplication mutations. Duchenne muscular dystrophy (DMD) is characterized by progressive muscle loss and c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Fluorescence lifetime imaging device for 5-ALA-guided neurosurgery

    SBC: HILIGHT SURGICAL, INC.            Topic: 394

    PROJECT SUMMARY 5-ALA-induced PpIX fluorescence-guided surgery (FGS) enables real-time visualization of residual cancer tissue during resection of brain tumors. This addresses a critical need in surgical oncology as the ability to identify residual tumor leads to improvements in overall survival, whereas the sparing of normal tissue benefits the patient’s quality of life. Currently, surgeons vis ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease

    SBC: CALIMETRIX LLC            Topic: NIBIB

    PROJECT SUMMARYThe overall goal of this Phase I proposal is to design and test the feasibility of novel magnetic resonance imaging (MRI) reference standards (“phantoms”) that are urgently needed for comprehensive and standardized quality assurance (QA) of quantitative MRI biomarkers of non-alcoholic fatty liver disease (NAFLD). We propose to develop 1) a quantitative MR elastography (MRE) stif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A dual-acting small molecule for the treatment of type 1 diabetes

    SBC: Asake Biotechnology, LLC            Topic: NIDDK

    Project Summary: Over 1.5 million Americans suffer from type 1 diabetes (T1D), an autoimmune disorder involving insulin, a hormone that is essential for blood glucose regulation and overall energy metabolism. When first diagnosed with T1D, it is estimated that the patient’s insulin has been reduced by 70-90%. By this point, the immune system has already targeted and destroyed a vast majority of ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage

    SBC: THE TINY CARGO COMPANY            Topic: 102

    Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects of cancer radiation therapy (RT). Our therapeutic is comprised of milk-derived extracellular vesicles (mEVs) loaded with a safe and highly effective radioprotective drug – a formulation that we call Milactatm. RT compli ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension

    SBC: Sensydia Corporation            Topic: NHLBI

    PROJECT SUMMARY Heart failure (HF) and abnormal heart function directly affects 6 million people in the U.S. and is a leading cause of death. Early intervention is key to reducing mortality and morbidity, yet early diagnosis, particularly for those with asymptomatic disease, is challenging. Effective diagnosis and management of HF and accompanying pulmonary hypertension (PH) requires accurate meas ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government